VX680/MK-0457, a potent and selective aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma

American Journal of Translational Research

Volumn 2, Issue 3, 2010, Pages 296-308

  Li, Yan ^a,b   Zhang, Zhong Fa ^a   Chen, Jindong ^a   Huang, Dan ^a   Ding, Yan ^a   Tan, Min Han ^a,c,d   Qian, Chao Nan ^a,c,e   Resau, James H ^a   Kim, Hyung ^f   Teh, Bin Tean ^a,c  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Aurora; Aurora kinase; MK 0457; Renal cell carcinoma; VX680

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MALE; MICROARRAY ANALYSIS; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TARGET CELL; TUMOR CELL; TUMOR XENOGRAFT;

EID: 77954677274     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
3. Rini BI, Flaherty K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 2008; 26: 543-549.
4. Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009; 64: 11-25.
5. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14: 1639-1648.
6. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786: 60-72.
7. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-854.
8. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003; 22: 451-464.
9. Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, Teh BT. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 2008; 68: 81-88.
10. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/ transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33: e175.
11. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
12. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
13. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
14. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis CD, Sassone-Corsi P. Mitotic phosphorylation of histone H3: spatiotemporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002; 22: 874-885.
15. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-267.
16. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 55-62.
17. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279: 52175-52182.
18. Qin L, Tong T, Song Y, Xue L, Fan F, Zhan Q. Aurora-A interacts with Cyclin B1 and enhances its stability. Cancer Lett 2009; 275: 77-85.
19. Dreier MR, Grabovich AZ, Katusin JD, Taylor WR. Short and long-term tumor cell responses to Aurora kinase inhibitors. Exp Cell Res 2009; 315: 1085-1099.
20. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX 680 induces endoreduplication and apoptosis preferentially in cells with compromised p53 dependent postmitotic checkpoint function. Cancer Res 2006; 66: 7668-7677.
21. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Jr., Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008; 14: 5437-5446.
22. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K, Adams JL, Dhanak D, Yang J, Lai Z, Sutton D, Patrick D. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009; 8: 1808-1817.
23. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL, Hsiao PW. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009; 15: 840-850.